Insider Transactions in Q1 2021 at Incyte Corp (INCY)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
298
+5.53%
|
$24,138
$81.27 P/Share
|
|
Mar 31
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
225
+1.49%
|
$18,225
$81.27 P/Share
|
|
Mar 31
2021
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
219
+7.47%
|
$17,739
$81.27 P/Share
|
|
Mar 31
2021
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
251
+4.36%
|
$20,331
$81.27 P/Share
|
|
Mar 31
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
728
+0.01%
|
-
|
|
Mar 29
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Open market or private sale
|
Direct |
20,000
-30.56%
|
$1,620,000
$81.08 P/Share
|
|
Mar 12
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
128
+0.42%
|
$8,320
$65.36 P/Share
|
|
Mar 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
395
-1.4%
|
$31,205
$79.73 P/Share
|
|
Feb 23
2021
|
Herve Hoppenot Chairman / CEO |
BUY
Open market or private purchase
|
Direct |
12,925
+4.35%
|
$995,225
$77.37 P/Share
|
|
Feb 16
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
127
+0.42%
|
$8,255
$65.36 P/Share
|
|
Feb 11
2021
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,210
-3.58%
|
$101,640
$84.99 P/Share
|
|
Feb 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,356
-2.32%
|
$122,040
$90.0 P/Share
|
|
Feb 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
961
+3.16%
|
$62,465
$65.42 P/Share
|
|
Jan 25
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.29%
|
$7,800
$100.5 P/Share
|
|
Jan 25
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.12%
|
$7,800
$100.5 P/Share
|
|
Jan 25
2021
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
2,744
-5.2%
|
$274,400
$100.0 P/Share
|
|
Jan 25
2021
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
5,116
-8.42%
|
$506,484
$99.0 P/Share
|
|
Jan 25
2021
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Exercise of conversion of derivative security
|
Direct |
4,116
+11.63%
|
$296,352
$72.86 P/Share
|
|
Jan 25
2021
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,795
-3.07%
|
$379,500
$100.0 P/Share
|
|
Jan 25
2021
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,795
+2.98%
|
$258,060
$68.62 P/Share
|
|
Jan 25
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Open market or private sale
|
Direct |
21,545
-6.64%
|
$2,154,500
$100.0 P/Share
|
|
Jan 25
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
BUY
Exercise of conversion of derivative security
|
Direct |
21,545
+5.97%
|
$1,572,785
$73.21 P/Share
|
|
Jan 19
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-0.64%
|
$16,182
$93.96 P/Share
|
|
Jan 19
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-0.26%
|
$16,182
$93.96 P/Share
|
|
Jan 15
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
BUY
Grant, award, or other acquisition
|
Direct |
5,761
+17.38%
|
-
|
|
Jan 15
2021
|
Paul Trower Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,032
+12.42%
|
-
|
|
Jan 15
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
17,283
+12.09%
|
-
|
|
Jan 15
2021
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
11,522
+17.93%
|
-
|
|
Jan 15
2021
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,044
+16.14%
|
-
|
|
Jan 15
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
BUY
Grant, award, or other acquisition
|
Direct |
11,522
+7.42%
|
-
|
|
Jan 15
2021
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,522
+25.41%
|
-
|
|
Jan 11
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
127
+0.42%
|
$8,255
$65.36 P/Share
|
|
Jan 04
2021
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
136
-0.62%
|
$11,696
$86.45 P/Share
|
|
Jan 04
2021
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
136
-0.28%
|
$11,696
$86.45 P/Share
|